CHINARES PHARMA Announces Board Changes: Guo Chuan Resigns, Zhang Jing Joins as Non-Executive Director

Bulletin Express
07/13

China Resources Pharmaceutical Group Limited reported that, effective 13 July 2026, Mr. Guo Chuan has stepped down from his position as non-executive director citing other work commitments. The company confirmed that Mr. Guo has no disagreements with the Board and no matters need to be brought to shareholders’ attention. The Board expressed appreciation for his contributions during his tenure.

Concurrently, the Board appointed Mdm. Zhang Jing, aged 57, as a non-executive director with effect from the same date. Zhang’s public-sector experience spans over two decades, including senior roles at the Beijing Municipal Finance Bureau and the State-owned Assets Supervision and Administration Commission of Beijing Municipality. Since September 2023, she has served as chief accountant at Beijing State-owned Capital Operation and Management Company Limited. She holds a Master’s degree in Project Management from a joint programme between Tianjin University of Technology and the University of Quebec at Chicoutimi and carries the professional title of Senior Accountant.

Zhang enters the Board without a fixed-term service contract and will be subject to retirement by rotation and re-election in accordance with the company’s articles of association. She will not receive director’s emoluments and holds no shares in the company or its associated corporations. The company confirmed she maintains no relationships with existing directors, senior management, or substantial shareholders and has not served as a director of any other listed companies in the past three years.

Following these changes, the Board now comprises one chairman/executive director, two additional executive directors, five non-executive directors, and four independent non-executive directors.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10